Psoriatic Arthritis

Phase 2b/3 data show durable ACR50/70, PASI90/100, and minimal disease activity responses with izokibep through one year.

Guselkumab (Tremfya) was originally approved in 2020, with its indication expanded to pediatric patients with psoriatic arthritis in 2025.

Findings will be presented at the EULAR Annual Meeting and show significantly more bimekizumab-treated patients achieved the 16 week ACR50 primary endpoint.

Real-world data suggest IL-23 biologics may cut 3-year psoriatic arthritis risk in psoriasis versus TNF and IL-17 therapies.

The findings extend the radiographic dataset for risankizumab in PsA to 244 weeks — the longest such follow-up reported from the KEEPsAKE program.

Additional data from the BE BOLD trial supporting bimekizumab over risankizumab are slated for a future medical conference.

The FDA has set a PDUFA of October 29, 2026, for the therapy's application.

This rheumatology month in review emphasizes impactful conversations from RWCS 2026 and the launch of the Joint Ventures podcast.

Full data from BE BOLD supporting bimekizumab over risankizumab are expected at a future medical meeting.

The decision is made off findings from the 2 phase 3, randomized, double-blind, placebo-controlled POETYK PsA-1 and POETYK PsA-2 trials.

This rheumatology month in review emphasizes new data and FDA actions.

Mease discussed the latest updates on deucravacitinib and zasocitinib at ACR Convergence 2025.

A groundbreaking study reveals that combining ixekizumab and tirzepatide significantly improves outcomes for adults with psoriatic arthritis and obesity.

This rheumatology month in review emphasizes new data and impactful approvals.

The Q4 recap for rheumatology spotlights regulatory and clinical advances across rheumatic diseases.

The rheumatology year in review highlights FDA approvals and pivotal data readouts.

The asthma year in review highlights FDA approvals, data, and advances in 2025.

Explore five pivotal FDA decisions set for early 2026 that could transform specialty medicine and enhance treatment options across various conditions.

This rheumatology month in review emphasizes new data from the ACR Convergence.

Mease discussed the latest updates on apremilast and growing attention to cardiometabolic outcomes at ACR Convergence 2025.

At the SDPA Fall Conference, Singla speaks in an interview regarding screening patients with psoriasis for psoriatic arthritis (PsA).

Explore the complexities of psoriatic arthritis, its symptoms, and the importance of multidisciplinary management for effective treatment.

Mease discussed the latest updates on bimekizumab, sonelokimab, and izokibep at ACR Convergence 2025.

Behrens discussed strong data supporting secukinumab's use over ustekinumab post-TNF inhibitor in PsA.

In long-term follow-up of KEEPsAKE 1 and 2, risankizumab maintained joint, skin, pain, and axial responses in patients with PsA through 244 weeks.